Financing repurposed drugs for rare diseases: a case study of Unravel Biosciences.

Bechara AbouarabChristian BazarianZied Ben ChaouchAndrew W LoGuillermo Mourenza GonzalezRichard NovakFrederic Vigneault

Published in: Orphanet journal of rare diseases (2023)

Repurposing existing compounds offers important advantages that could help early-stage biotech startups better align their business and financing issues with their scientific and medical objectives, enter a space that is not occupied by large pharmaceutical companies, and accelerate the validation of their drug development platform.

Keyphrases

early stage
healthcare
high throughput
sentinel lymph node
drug induced
single cell